The utilization of TAT following PCI among high-stroke risk AF patients steadily increased from 2011 to 2020, reaching 65.4% by the end of the study period. However, in 2020, a significant proportion of 29.4% of patients still received DAPT, indicating that many AF patients undergoing PCI did not receive adequate antithrombotic therapy.
Keyphrases
- atrial fibrillation
- percutaneous coronary intervention
- end stage renal disease
- patients undergoing
- antiplatelet therapy
- coronary artery disease
- acute myocardial infarction
- newly diagnosed
- ejection fraction
- acute coronary syndrome
- chronic kidney disease
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- peritoneal dialysis
- heart failure
- patient reported outcomes
- brain injury
- bone marrow